Mangrove Partners’s ChemoCentryx, Inc. CCXI Stock Holding History

Mangrove Partners’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-686,300	Closed	-$11.7M	–	629
2021 Q3	$11.7M	Buy	+686,300	New	+$10.7M	1.05%	13

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Mangrove Partners's CCXI Position: Q1 2022 in Review

Mangrove Partners sold out of ChemoCentryx, Inc. (CCXI) in Q1 2022, closing a stake of 39,774 shares — an estimated $1.45M sold.

Mangrove Partners first reported a position in CCXI in Q1 2020 and held it in 4 quarters. The position peaked at $23.6M in Q1 2020. 176 funds tracked by Wall St. Rank hold CCXI as of Q1 2022.

Mangrove Partners reported no remaining ChemoCentryx, Inc. position as of Q1 2022 after selling out during the quarter.
Mangrove Partners sold 39,774 ChemoCentryx, Inc. shares in Q1 2022, an estimated $1.45M.
Mangrove Partners first reported a position in ChemoCentryx, Inc. in Q1 2020 and held it in 4 quarters.
Mangrove Partners's ChemoCentryx, Inc. position peaked at $23.6M in Q1 2020.
176 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.